Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-08-09
2011-08-09
Zara, Jane (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S006120, C435S091100, C435S091310, C435S325000, C435S455000, C536S023100, C536S024500
Reexamination Certificate
active
07994144
ABSTRACT:
Described are compositions and methods relating to gene therapy, particularly as applied to hematopoietic progenitor (HP) cells, to transduced cells and methods of obtaining them, and to methods of using them to provide prolonged engraftment of modified hematopoietic cells in human subjects. The invention particularly relates to ex vivo gene therapy of HP cells for treatment or prevention of HIV infection.
REFERENCES:
patent: 5026687 (1991-06-01), Yarchoan et al.
patent: 5500357 (1996-03-01), Taira et al.
patent: 5525468 (1996-06-01), McSwiggen
patent: 5693535 (1997-12-01), Draper et al.
patent: 5712384 (1998-01-01), Symonds et al.
patent: 5911983 (1999-06-01), Barranger et al.
patent: 6060317 (2000-05-01), Malech
patent: 6114167 (2000-09-01), Symonds et al.
patent: 6287864 (2001-09-01), Bagnis et al.
patent: 2002/0058636 (2002-05-01), Symonds et al.
patent: 2003/0082158 (2003-05-01), Symonds et al.
patent: 2004/0072771 (2004-04-01), Symonds et al.
patent: 2004/0072772 (2004-04-01), Ruggieri et al.
patent: 3/21201 (1989-06-01), None
patent: 6/12844 (1994-08-01), None
patent: 1298208 (2003-04-01), None
patent: 2005-521632 (2005-07-01), None
patent: WO 91/04324 (1991-04-01), None
patent: WO 92/17211 (1991-04-01), None
patent: WO 94/00012 (1994-01-01), None
patent: WO 94/16736 (1994-08-01), None
patent: WO 95/04818 (1995-02-01), None
patent: WO 95/18854 (1995-08-01), None
patent: WO 96/22368 (1996-07-01), None
patent: WO 9633281 (1996-10-01), None
patent: WO 97/47770 (1997-12-01), None
patent: WO 00/34495 (2000-06-01), None
patent: WO 02/059300 (2002-07-01), None
patent: WO 03/006612 (2003-01-01), None
patent: WO 03/006691 (2003-01-01), None
Bahner et al. (1996) J. Virology 70:4352-4360.
Amado et al. (1999) Program Abstr. 6th Conf. Retrovir. Oppor. Infect Conf. Retrovir. Oppor. Infect 6th 1999 Chic. III. Jan. 31-Feb. 4, 1999; 6th: 70 (Abstract No. 17).
Hanenberg et al. (1997) Human Gene Ther. 8:2193-2206.
Gervaix et al. (1997) Human Gene Ther. 8:2229-2238.
Perez-Simon et al. (1998) Transfusion 38:385-391.
Bender et al. (1992) J. Hematotherapy 1:329-341.
Verma, I.M. et al., Nature, vol. 389, pp. 239-242 (1997).
File History of U.S. Appl. No. 11/506,722, filed Aug. 18, 2006, Symonds et al.
Abonour, “Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human lone-term repopulating hematopoietic stem cells”,Nature Medicine, vol. 6, No. 6, pp. 652-658 (2000).
Abonour, Abstract #172, [online] 1997 Retrieved from Internet: URL:http://www4.od.nih.gov/oba/rac/hgtprep.asp.
Aguila, H.L., K. Akashi, J. Domen, K.L. Gandy, E. Lagasse, R.E. Mebius, S.J. Morrison, J. Shizuru, S. Strober, N. Uchida, D.E. Wright & I.L. Weissman (1997). “From stem cells to lymphocytes: biology and transplantation.”Immunol. Rev. 157: 13-40.
Akhtar t al., (1996) “Anti-HIV Therapy with Antisense Oligonucleotides and Ribozymes: Realistic Approaches or Expensive Myths”,J. Antimicrob. Chemother., vol. 38, pp. 159-165.
Amado et al. “A Phase I gene therapy clinical study of autologous CD34+cells transduced with an anti-HIV-1 ribozyme,”40th Meeting of the American Society of Hematology, Miami, 1998.
Amado, Rafael, “A phase I trial of autologous CD34+ hematopoietic progenitor cells transduced with Anti-HIV Ribozyme,”Human Gene Therapy, 1999; 10: 2225-2270.
Amado et al. “Development of genetically protected T-lymphocytes from transduced hematopoietic progenitors in human immunodeficiency virus-1 infected patients,”14thInternational AIDS Conference, Barcelona, 2002.
Amado et al. “Multilineage engraftment and preferential survival of ribozyme containing CD4+ T-lymphocytes derived from CD34+ progenitor cells in a phase I study in HIV-1,”5thAm Soc Gener Therapy Meeting, 2002.
Amado et al., “Effects of Megakaryocyte Growth and Development Factor on Survival and Retroviral Transduction of T Lymphoid Progenitor Cells”,Human Gene Therapy9:173-183 (1998).
Amado et al., A phase I gene therapy trial of autologous CD34+ cells transduce with an anti-HIV ribozyme,Conf. Retroviruses Opportunistic Infect. Jan. 31- Feb. 4, 1999; 6th: 70 (abstract No. 17).
Amado, Systemix #261, [online] 1998 pp. 11-13 URL:http://www4.od.nih.gov/oba/rac/hgtprep.asp.
Amado, Systemix #277, [online] 1998 p. 15-16 URL:http://www4.od.nih.gov/oba/rac/hgtprep.asp.
Bai J, Gorantla S, Banda N, Cagnon L, Rossi J, Akkina R. Characterization of anti-CCR5 ribozyme-transduced CD34+ hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo.Mol Ther. 2000; 1:244-54.
Barinaga,“Ribozymes: Killing the Messenger,”Science262:1512 (1993).
Barranger, JA, Scientific Summary #46, [online] 1993 URL:http://www4.od.nih.gov/oba/rac/hgtprep.asp.
Bauer et al., “Gene Therapy for Pediatric AIDS”Annals of the New York Academy of Sciences, 2000, vol. 918, pp. 318-329.
Bauer, Scientific Abstract #204 [online] 1997, URL:http://www4/od.nih.gov/oba/rac/hgtprep.asp.
Baum, C.M., I.L. Weissman, A.S. Tsukamoto, A.-M. Buckle and B.Peault (1992) “Isolation of a candidate human hematopoietic stem-cell population.”Proc Natl Acad Sci USA89:2804-2808.
Bauer et al., (1997) “Inhibition of Human Immunodeficiency Virus-1 (HIV-1) Replication After Transduction of Granulocyte Colony-Stimulating Factor-Mobilized CD34+Cells From HIV-1-Infected Donors Using Retroviral Vectors Containing Anti-HIV-1 Genes,”Blood89 :2259-2267.
Bender, M.A., Palmer, T.D., Gelinas, R.E. & Miller, A.D. (1987). Evidence that the Packaging Signal of Moloney Murine Leukemia Virus Extends into the gag Region.J. Virol., 61, 1639-1646.
Berzal-Herranz, A. et al. “Essential Nucleotide Sequences and Secondary Structure Elements of the Hairpin Ribozyme.” EMBO 12:2567-2574 (1993).
Bevec, D. et al., “Inhibition of Human Immunodeficiency Virus Type 1 Replication in Human T Cells by Retroviral-Mediated Gene Transfer of a Dominant-Negative Rev Trans-Activator.”Proc. Natl. Acad. Sci. 89:9870-9874 (1992).
Bischofberger, N. and Wagner, R.W. “Antisense Approaches to Antiviral Agents”.Virology3:57-66 (1992).
Amado et al. (1998) “A Phase I gene therapy clinical study of autologous CD34+cells transduced with an anti-HIV-1 ribozyme,”Blood, 92 (10), Supplement 1, part 1-2, p. 665a, Abstract # 274340th Meeting of the American Society of Hematology, Miami.
Bodine et al., (1998) “Improved Amphotropic Retrovirus-Mediated Gene Transfer into Hematopoietic Stem Cells,”Ann NY Acad Sci850: 139-50.
Bonyhadi et al., (1997) “RevM10-Expressing T Cells Derived In Vivo from Transduced Human Hematopoietic Stem-Progenitor Cells Inhibit Human Immunodeficiency Virus Replication,”J Virol71:4704-16.
Bordignon et al., “Gene Therapy in Peripheral Blood Lymphocytes and bone Marrow for ADA−Immunodeficient Patients,”Sciencevol. 270, 470-475 (1995).
Briones et al., (1999) “Retroviral gene transfer into human hematopoietic cells an in vitro kinetic study,”Haematologica84 :483-488.
Buckley, Abstract #446, [online] 2001 Retrieved from Internet: URL:http://www4.od.nih.gov/oba/rac/hgtprep.asp.
Calenda et al., “The Effects of HIV on Hematopoiesis”European Journal of Haematology, 1992, 48: 181-186.
Carabasi, Systemix #340 (Protocol 108), [online] 1999 pp. 13-16 URL:http://www4.od.nih.gov/oba/rac/hgtprep.asp.
Carr et al. “A Phase I Gene Therapy Study showing safety, feasibility and sustained survival of anti-HIV-I transduced CD4+ lymphocytes”,6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999.
Case et al., (1999) “Stable transduction of quiescent CD34+CD38−Human hematopietic cells by HIV-1-based lentiviral vectors,”Proc Natl Acad Sci USA96:2988-93.
Castanotto, D. et al. (2000). “Human gene therapy and genetically modified stem cells for the treatment of AIDS,” Abstract, Third Annual Meeting of the American Society of Gene Therapy.
Cavazzana-Calvo, “Gene Thera
Amado Rafael
Fanning Greg
Gerlach Wayne
Macpherson Janet
Sun Lun-Quan
Cooper & Dunham LLP
Johnson & Johnson Research Pty Limited
White John P.
Zara Jane
LandOfFree
Process for the preparation of a composition of genetically... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for the preparation of a composition of genetically..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for the preparation of a composition of genetically... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2689211